#USA #New York #Gross Law Firm #INOVIO Pharmaceuticals #SEC Class Action

Important Notice for Inovio Pharmaceuticals Shareholders

The Gross Law Firm has recently alerted shareholders of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) about the upcoming deadlines related to a securities class action lawsuit. Shareholders who purchased shares during a specific class period are encouraged to participate in the proceedings for potential recovery.

Key Class Period Details

The class period for this lawsuit spans from October 10, 2023, to December 26, 2025. During this time, the complaint alleges that Inovio issued materially false and misleading statements regarding its operations and product development. Specifically, the allegations center around issues with the manufacturing of Inovio's CELLECTRA device, which the company claimed was essential for its lead product candidate, INO-3107. The lawsuit suggests that Inovio's prospects for regulatory approval were overstated, impacting the company's stock value significantly.

Understanding the Allegations

Investors should note several critical claims made in the lawsuit:
1. Manufacturing Deficiencies: It is alleged that the production of Inovio's CELLECTRA device did not meet industry standards, raising concerns over the product's reliability.
2. Regulatory Delays: The timeline for submitting the application for FDA approval for INO-3107, initially expected in late 2024, is now uncertain.
3. Misleading Public Statements: The class action contends that Inovio's public statements during this period may have misrepresented the company’s overall regulatory and commercial outlook.

Next Steps for Shareholders

Shareholders are urged to register their information promptly to be included in this case. Registration not only allows stakeholders to monitor the status of their claims but also enables participation in any recovery efforts should the lawsuit yield favorable outcomes. The deadline for shareholders to seek lead plaintiff status is April 7, 2026. Importantly, there is no cost incurred for participating in the legal process.

Why Choose Gross Law Firm

The Gross Law Firm is recognized nationally for its role in class action lawsuits, particularly those involving securities. They emphasize a mission to safeguard the rights of investors who have fallen victim to corporate deceit and fraud. Their commitment lies in pushing for accountability among corporations and helping affected shareholders recover losses related to misleading statements made by companies.

How to Register for the Class Action

Shareholders who wish to participate in this class action lawsuit are advised to visit Gross Law Firm's dedicated webpage where they can provide their information securely. This step is crucial in ensuring that they receive all necessary updates and information relevant to the case.

For more information and to register, visit: Gross Law Firm Inovio Class Action

Conclusion

Inovio Pharmaceuticals shareholders are encouraged to act promptly as the April 7, 2026 deadline approaches. This lawsuit represents an opportunity for investors to seek justice and possibly recover losses from misleading corporate practices. Stay informed about developments through reliable sources and take proactive steps in safeguarding your investments.